22nd Century Group Inc.

At 14.6, the RSI is severely oversold, suggesting capitulation selling has dominated XXII recently—yet the stock sits nowhere near its 52-week high, indicating this isn't a rebound play. With a market cap below $100M and a P/E that can't be calculated (likely negative earnings), this is a speculative biotech-adjacent cigarette company with minimal fundamental footing. The 16.45% short interest combined with extreme oversold conditions creates theoretical squeeze potential, but the lack of profitability and microscopic valuation leave little margin for error. This feels less like a value opportunity and more like a distressed micro-cap where technical bounces can be violent but ultimately meaningless without a viable path to earnings.